Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy symbols : Tak save search
Plasma Therapy Global Market Report 2024 - Projected Compound Annual Growth Rate of 12.5%, with Market Set to Reach $0.88 Billion in 2028
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
BAX | $40.04 -0.72% -0.6% 3M
|
Health Technology
|
| O: -0.38%
H: 0.14%
C: -0.14%
KMDA | $5.15 -0.96% -0.97% 16K
|
Health Technology
|
| O: 2.0%
H: 2.28%
C: 1.63%
ADMA 4 | $5.975 -0.75% -0.75% 1.8M
|
Health Technology
|
| O: 0.19%
H: 2.5%
C: 1.35%
report reach global set therapy growth market
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $63.874 -4.38% 11K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.38%
H: 0.78%
C: 0.78%
hyqvia approved therapy
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.27%
H: 0.61%
C: -0.2%
ohb-607 license group oak agreement therapy
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.79%
hyqvia chmp positive therapy
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2023-09-13 (Crawled : 13:30) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.63%
H: 0.5%
C: 0.31%
entyvio fda disease active therapy
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Published: 2023-07-20 (Crawled : 00:00) - globenewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.65%
H: 0.49%
C: 0.07%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.35%
H: 2.21%
C: 1.9%
HCM | $17.64 -1.34% -1.36% 63K
|
Health Technology
|
| O: -0.33%
H: 2.55%
C: 1.4%
treatment designation china therapy study
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Published: 2023-06-20 (Crawled : 14:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.25%
H: 0.31%
C: -0.12%
hyqvia meeting set trial therapy
Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published: 2023-05-15 (Crawled : 17:00) - prnewswire.com
GNMSF | $291.12 3.83% 300
|
Health Technology
|
| O: 0.24%
H: 0.66%
C: 0.66%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.61%
H: 0.3%
C: 0.24%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.2%
H: 0.13%
C: -0.22%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.27%
H: 0.6%
C: 0.41%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
GMAB | $29.51 0.85% 0.85% 500K
|
Health Technology
|
| O: 0.38%
H: 0.91%
C: 0.69%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.28%
C: 0.11%
report cancer global therapy growth market
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Published: 2023-04-27 (Crawled : 13:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.36%
C: 0.3%
entyvio fda active resubmission therapy
Stem Cell Therapy Global Market Report 2022: Advancements in Stem Cell Clinical Trials Fuels Growth
Published: 2023-04-05 (Crawled : 23:00) - prnewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 1.24%
H: 2.42%
C: 1.94%
report cell trials global therapy growth market
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
Published: 2023-02-22 (Crawled : 22:00) - globenewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.32%
H: 0.44%
C: 0.0%
CDXS | $2.69 -6.27% -6.69% 490K
|
Process Industries
|
| O: 1.09%
H: 0.09%
C: -1.26%
therapy
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Published: 2023-01-11 (Crawled : 14:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 1.04%
H: 0.32%
C: 0.19%
exkivity approval therapy
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
Published: 2022-10-20 (Crawled : 12:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.6%
H: 0.6%
C: 0.04%
pharma disease collaboration agreement therapy
The Worldwide Enzyme Replacement Therapy Industry is Expected to Reach $15 Billion by 2028
Published: 2022-09-16 (Crawled : 14:20) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.15%
H: 1.04%
C: 0.15%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 0.62%
H: 1.01%
C: 0.46%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: -0.95%
H: 1.21%
C: 1.1%
FOLD | $10.66 -4.99% -5.25% 2.5M
|
Health Technology
|
| O: -0.91%
H: 0.18%
C: -2.12%
expected therapy
Global Cell Therapy Manufacturing Market to Reach $6.01 Billion by 2026
Published: 2022-09-13 (Crawled : 11:00) - prnewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -1.17%
H: 0.15%
C: -1.47%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.72%
H: 0.07%
C: -1.27%
CTLT | $56.08 -0.39% 0.0% 1.6M
|
Health Technology
|
| O: -2.7%
H: 0.52%
C: -1.7%
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: -3.41%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.25%
H: 0.05%
C: -4.29%
global therapy market
Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials
Published: 2022-09-01 (Crawled : 13:20) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.36%
H: 0.58%
C: 0.29%
isp-001 fda clearance trials application therapy mps-ih mps-i
Autologous Cell Therapy Market to Reach Value of US$ 34.7 Bn by 2027, States TMR Report
Published: 2022-08-15 (Crawled : 12:00) - prnewswire.com
USRM | $0.0001 1300.0% 290K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -3.28%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.63%
H: 0.85%
C: 0.56%
VCEL | $48.72 1.71% 1.68% 350K
|
Health Technology
|
| O: -1.03%
H: 9.88%
C: 9.66%
LCTX | $1.25 -3.85% 0.0% 670K
|
Health Technology
|
| O: -0.64%
H: 2.88%
C: 1.92%
report therapy market
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
Published: 2021-10-27 (Crawled : 20:00) - fda.gov
TMO | $557.87 -1.3% 0.0% 1M
|
Health Technology
|
| O: 0.44%
H: 2.01%
C: 0.82%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 2.03%
H: 3.33%
C: 0.07%
RGNX | $18.04 -0.28% -0.28% 350K
|
Health Technology
|
| O: 0.91%
H: 2.93%
C: 2.79%
BIIB | $196.76 -0.72% -0.72% 1.2M
|
Health Technology
|
| O: 0.19%
H: 2.32%
C: 1.7%
disease fda gene therapies therapy gene therapy rare
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
Published: 2021-10-27 (Crawled : 14:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.36%
H: 0.22%
C: -0.65%
solid tumors therapy
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.